Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rislenemdaz
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Cerecor
Deal Size : $22.1 million
Deal Type : Acquisition
Cerecor and Aevi Genomic Medicine Complete Merger
Details : Cerecor’s pipeline now includes six clinical-stage assets, accelerating the company’s transformation into a research organization focused on developing new medicines for unmet needs in rare diseases.
Product Name : CERC-301
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 02, 2020
Lead Product(s) : Rislenemdaz
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Cerecor
Deal Size : $22.1 million
Deal Type : Acquisition